Inhibition of the Class II HMG-CoA reductase of Pseudomonas mevalonii

被引:15
|
作者
Hedl, M [1 ]
Rodwell, VW [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
关键词
HMG-CoA reductase; Class IIHMG-CoA reductase; Pseudomonas mevalonii; isoprenoid biosynthesis; statin drug; Lovastatin;
D O I
10.1110/ps.03597504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are two structural classes of HMG-CoA reductase, the third enzyme of the mevalonate pathway of isopentenyl diphosphate biosynthesis-the Class I enzymes of eukaryotes and the Class II enzymes of certain eubacteria. Structural requirements for ligand binding to the Class II HMG-CoA reductase of Pseudomonas mevalonii were investigated. For conversion of mevalonate to HMG-CoA the -CH3, -OH, and -CH2COO- groups on carbon 3 of mevalonate were essential for ligand recognition. The statin drug Lovastatin inhibited both the conversion of HMG-CoA to mevalonate, and the reverse of this reaction. Inhibition was competitive with respect to HMG-CoA or mevalonate and noncompetitive with respect to NADH or NAD(+). K-i values were millimolar. The over 10(4)-fold difference in statin K-i values that distinguishes the two classes of HMG-CoA reductase may result from differences in the specific contacts between the statin and residues present in the Class I enzymes but lacking in a Class II HMG-CoA reductase.
引用
收藏
页码:1693 / 1697
页数:5
相关论文
共 50 条
  • [42] Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG-CoA reductase inhibition
    GonzalezMolina, M
    Cabello, M
    Tinahones, F
    Burgos, D
    Lillo, J
    Soriguer, F
    Calvar, C
    Rodriguez, MA
    NEFROLOGIA, 1996, 16 (04): : 359 - 364
  • [43] Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenyl-quinoline mevalonolactones
    Zhao, Shikui
    Zhou, Weicheng
    Liu, Jun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (23) : 7915 - 7923
  • [44] Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts
    Menéndez, R
    Amor, AM
    Rodeiro, I
    González, RM
    González, PC
    Alfonso, JL
    Más, R
    ARCHIVES OF MEDICAL RESEARCH, 2001, 32 (01) : 8 - 12
  • [45] Evaluation of HMG-CoA Reductase Inhibitors for Multiple SclerosisOpportunities and Obstacles
    Oliver Neuhaus
    Olaf Stüve
    Scott S. Zamvil
    Hans-Peter Hartung
    CNS Drugs, 2005, 19 : 833 - 841
  • [46] PHARMACOLOGY AND MECHANISM OF ACTION OF THE NEW HMG-COA REDUCTASE INHIBITORS
    SIRTORI, CR
    PHARMACOLOGICAL RESEARCH, 1990, 22 (05) : 555 - 563
  • [47] HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis
    Joel D. Mermis
    Steven Q. Simpson
    Current Infectious Disease Reports, 2012, 14 : 484 - 492
  • [48] Isorhamnetin derivatives and piscidic acid for hypercholesterolemia: cholesterol permeability, HMG-CoA reductase inhibition, and docking studies
    Asma Ressaissi
    Nebil Attia
    Pedro Luis Falé
    Rita Pacheco
    Bruno L. Victor
    Miguel Machuqueiro
    Maria Luísa M. Serralheiro
    Archives of Pharmacal Research, 2017, 40 : 1278 - 1286
  • [49] Inhibition of HMG-CoA reductase activity by hypercholesterolaemia reduces leukocyte recruitment and MCP-1 production
    Fruscella, P
    Romano, M
    Albani, D
    Bernasconi, S
    Luini, W
    Bruno, A
    Salmona, M
    Diomede, L
    CYTOKINE, 2000, 12 (07) : 1100 - 1103
  • [50] Lipid-Producing Ciliochoroidal Melanoma with Expression of HMG-CoA Reductase
    Van Ly, David
    Wang, Duo
    Conway, Robert Max
    Giblin, Michael
    Liang, Sharron
    Lukeis, Robyn
    Lim, Li-Anne
    Hesson, Luke
    Cherepanoff, Svetlana
    OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (06) : 416 - 421